Compare Johnson & Johnson (JNJ) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B). The key difference: Johnson & Johnson is far larger — about 3.7× Vanguard Emerging Markets Stock Index Fund ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| JNJ | VWO | |
|---|---|---|
Market Cap | $618.09B | $168.50B |
Volume | 6,050,983 | 9,650,999 |
Sector | Health | — |
52-Week High | $278.43 | $61.44 |
52-Week Low | $186.00 | $52.42 |
Typical Hold Time | 129 Days | 135 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
VWO trades at $59.76, down 0.15% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF's emerging markets focus faces headwinds from China's economic slowdown, though AI-driven semiconductor demand in Taiwan provides some offset. Recent institutional buying by firms like Allianz and Alamar Capital suggests confidence in long-term emerging markets exposure despite near-term challenges.
The outlook remains cautious given China's persistent weakness and technical bearish signals, though institutional accumulation and AI infrastructure spending offer potential catalysts. Key risks include concentrated emerging markets exposure and currency volatility, requiring careful position sizing for investors seeking diversification beyond developed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
